Trial Profile
A phase II trial of EQ001 in chronic graft-versus-host disease (cGVHD)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2018
Price :
$35
*
At a glance
- Drugs Itolizumab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 06 Dec 2018 New trial record
- 15 Nov 2018 According to an Equillium media release, the company expects to initiate this study in the first half of 2019.